MiNK Therapeutics, Inc. (NASDAQ:INKT) Short Interest Update

MiNK Therapeutics, Inc. (NASDAQ:INKT) saw a significant growth in short interest during the month of December. As of December 15th, there was short interest totalling 47,200 shares, a growth of 9.8% from the November 30th total of 43,000 shares. Currently, 0.5% of the company’s shares are short sold. Based on an average daily trading volume, of 46,800 shares, the short-interest ratio is presently 1.0 days.

Analysts Set New Price Targets

Several analysts have issued reports on the company. Robert W. Baird dropped their target price on MiNK Therapeutics from $8.00 to $4.00 and set an “outperform” rating for the company in a report on Friday, November 15th. HC Wainwright reissued a “buy” rating and issued a $9.00 price objective on shares of MiNK Therapeutics in a report on Friday, November 15th.

MiNK Therapeutics Stock Performance

INKT opened at $0.70 on Thursday. The stock has a market capitalization of $27.62 million, a PE ratio of -1.79 and a beta of 0.10. MiNK Therapeutics has a one year low of $0.46 and a one year high of $1.90. The business’s 50 day moving average price is $0.67 and its 200 day moving average price is $0.77.

Hedge Funds Weigh In On MiNK Therapeutics

A hedge fund recently raised its stake in MiNK Therapeutics stock. Renaissance Technologies LLC boosted its stake in MiNK Therapeutics, Inc. (NASDAQ:INKT) by 21.5% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 127,841 shares of the company’s stock after buying an additional 22,613 shares during the period. Renaissance Technologies LLC owned approximately 0.37% of MiNK Therapeutics worth $121,000 at the end of the most recent quarter. Institutional investors own 2.87% of the company’s stock.

MiNK Therapeutics Company Profile

MiNK Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials.